Gardasil 9 syringe 0.5ML
Ended Awarded
- Contract number
- SPE2DB25FC72J
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,263
Award facts
- Contract value 100% obligated
- $17,263.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $17,263.23 delivery order to AmerisourceBergen Drug Corp for GARDASIL 9 syringes (0.5mL) under a firm fixed-price contract. The award was made on August 12, 2025, with an ultimate completion date of August 13, 2025, and was not designated as a set-aside contract. Performance will occur at the contractor's location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was competitively selected through this non-set-aside procurement. The company maintains a significant role in federal medical procurement, particularly within the Defense Logistics Agency's Medical Supply Chain, where it supplies a comprehensive range of pharmaceutical products including vaccines, medications, and medical supplies across multiple therapeutic domains. GARDASIL 9, a human papillomavirus vaccine, represents a critical medical commodity for military and federal healthcare systems. The DLA's Pharmaceutical Prime Vendor Global Program Generation V contracts are anticipated to involve multiple regional awards with different contractors, positioning AmerisourceBergen to continue serving military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB25FC72J?
SPE2DB25FC72J was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 12, 2025.
How much is contract SPE2DB25FC72J worth?
The government has obligated $17,263 on SPE2DB25FC72J.
Is contract SPE2DB25FC72J an order under another contract?
Yes. SPE2DB25FC72J is a delivery order under SPE2DB20D2014, an indefinite delivery contract.
Was contract SPE2DB25FC72J competed?
The extent of competition for SPE2DB25FC72J was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award